Researchers from the National Institute of Allergy and Infectious Diseases (NIAID) have conducted a small clinical trial of a prime-boost for H7N9 influenza vaccines to provoke a better, stronger immune response against the virus.
Scientists have conducted clinical trials of prime boost H7N9 influenza candidate vaccines to determine whether these vaccines offer the necessary immune response against the influenza virus. The vaccines were developed by using inactivated viruses that have been proved safe for people. Unfortunately, it appears that the candidates would need several doses or several more adjuvants to create a strong immune response.
The boost is based on live, weakened influenza strains. Results from the study, which involved 65 volunteers between the ages of 18 and 70, show that when the boost is used along with the vaccine, it produces a stronger immune response.
In 2013, the H7N9 influenza first appeared in China. The people who are most impacted by the virus are ones who have contact with and exposure to poultry. In November, the World Health Organization confirmed 681 H7N9 cases with 275 deaths.
The U.S. has not detected any H7N9 influenza cases.
